依诺肝素序贯华法林治疗急性肺栓塞的临床效果  

Clinical Efficacy of Enoxaparin Sequential Warfarin in the Treatment of Acute Pulmonary Embolism

作　　者：白洋 BAI Yang(Beijing Huairou Hospital,Beijing 101400,China)

机构地区：[1]北京怀柔医院,北京101400

出　　处：《中外医学研究》2025年第4期45-49,共5页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探究依诺肝素序贯华法林治疗急性肺栓塞(APE)的临床效果。方法:选择2022年1月—2024年1月在北京怀柔医院治疗的80例APE患者,应用随机数表法将其分为对照组(依诺肝素)及观察组(依诺肝素序贯华法林),各40例。对比两组临床疗效、炎症因子、凝血功能、血管内皮功能、肺功能、不良反应。结果:观察组总有效率为95.0%,高于对照组的77.5%,差异有统计学意义(P<0.05)。治疗后,两组中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)、C反应蛋白(CRP)、肌钙蛋白I(TnI)、B型利钠肽(BNP)、D-二聚体(D-D)降低,一氧化氮(NO)、第1秒用力呼气容积(FEV_(1))、第1秒用力呼气占预计值的百分比(FEV_(1)%pred)、用力肺活量占预计值的百分比(FVC%pred)均升高,观察组上述指标优于对照组,差异有统计学意义(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:APE患者采用依诺肝素序贯华法林治疗,可降低炎症因子,改善心肺功能,促进血管内皮功能修复,安全性较高。Objective:To explore the clinical efficacy of Enoxaparin sequential Warfarin in the treatment of acute pulmonary embolism(APE).Method:A total of 80 patients with APE who were treated at Beijing Huairou Hospital from January 2022 to January 2024 were selected and randomly divided into control group(Enoxaparin)and observation group(Enoxaparin sequential Warfarin)by random number table method,40 cases in each group.The clinical efficacy,inflammatory factors,coagulation function,vascular endothelial function,lung function,and adverse reactions of the two groups were compared.Result:The total effective rate of the observation group was 95.0%,which was higher than 77.5%of the control group,and the difference was statistically significant(P<0.05).After treatment,the neutrophil to lymphocyte ratio(NLR),platelet to lymphocyte ratio(PLR),C-reactive protein(CRP),troponin I(TnI),B-type natriuretic peptide(BNP),D-dimer(D-D)decreased,nitric oxide(NO),forced expiratory volume at 1 second(FEV_(1)),percentage of forced expiratory volume at one second(FEV_(1)%pred),and percentage of forced vital capacity at 1 second(FVC%pred)all increased,the above indicators in the observation group were better than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion:Sequential treatment with Enoxaparin and Warfarin in APE patients can reduce inflammatory factors,improve cardiac and lung function,promote endothelial function repair,and have high safety.

关 键 词：依诺肝素 序贯 华法林 肺栓塞 凝血功能 肺功能 

分 类 号：R56[医药卫生—呼吸系统]